# Broadening Access, Creating Impact

Progress highlights in low- and middle-income countries (LMICs) July 2020 - March 2022 We're very proud of the progress we've made over the past two years to broaden access to medicines, particularly in view of the challenges posed by the COVID-19 pandemic. Together with our partners, we've acted on our commitment to strengthen local health care systems and address barriers to access at each stage of the patient journey.

Taked

# Countries where we have Access to Medicines programs



<sup>1</sup> These countries with evolving health care systems have been specifically identified as 'Access Countries' whereby the business strategy is focused on pro-actively investing to strengthen health care systems

# Our Access to Medicines approach



### Our progress in sub-Saharan Africa<sup>2</sup>



<sup>2</sup> Based on Takeda's internal data

### Our future priorities



#### **Broadening access**

- Expand our innovative financing models and affordability programs, and leveraging digital capabilities
- Deepen local policy engagement and shape discussions on key health care system priorities
- Drive local capacity building, informed by global best practice, to address barriers to access



#### Unlocking societal value through partnerships

- Expand Blueprint initiative into new markets to address gaps in health care capabilities and delivery
- Drive collective impact measurement through Access to Health Guidebook and Framework
- Equip local governments and actors to own and drive efforts for continuity and sustainable impact



#### Integrating our business approach

- Embed whole-of-organization approach to addressing access barriers, with shared responsibility across the business
- Leverage our Center of Excellence model to accelerate internal capacity building
- Empower local teams to deliver on access priorities through clear ownership and incentives